In order to see whether the decreased HIF-1α protein level was caused by accelerated proteasome degradation by ISL, we firstly added cycloheximide, a protein synthesis inhibitor, to treat breast cancer cells with or without ISL. Here, HIF1A is linked to breast carcinoma.